159 related articles for article (PubMed ID: 19221754)
1. Phase I study of bryostatin 1, a protein kinase C modulator, preceding cisplatin in patients with refractory non-hematologic tumors.
Pavlick AC; Wu J; Roberts J; Rosenthal MA; Hamilton A; Wadler S; Farrell K; Carr M; Fry D; Murgo AJ; Oratz R; Hochster H; Liebes L; Muggia F
Cancer Chemother Pharmacol; 2009 Sep; 64(4):803-10. PubMed ID: 19221754
[TBL] [Abstract][Full Text] [Related]
2. Phase Ib trial of bryostatin 1 in patients with refractory malignancies.
Grant S; Roberts J; Poplin E; Tombes MB; Kyle B; Welch D; Carr M; Bear HD
Clin Cancer Res; 1998 Mar; 4(3):611-8. PubMed ID: 9533528
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of prolonged infusion Bryostatin-1 in patients with advanced malignancies.
Marshall JL; Bangalore N; El-Ashry D; Fuxman Y; Johnson M; Norris B; Oberst M; Ness E; Wojtowicz-Praga S; Bhargava P; Rizvi N; Baidas S; Hawkins MJ
Cancer Biol Ther; 2002; 1(4):409-16. PubMed ID: 12432257
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion.
Jayson GC; Crowther D; Prendiville J; McGown AT; Scheid C; Stern P; Young R; Brenchley P; Chang J; Owens S
Br J Cancer; 1995 Aug; 72(2):461-8. PubMed ID: 7640233
[TBL] [Abstract][Full Text] [Related]
5. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
Varterasian ML; Mohammad RM; Eilender DS; Hulburd K; Rodriguez DH; Pemberton PA; Pluda JM; Dan MD; Pettit GR; Chen BD; Al-Katib AM
J Clin Oncol; 1998 Jan; 16(1):56-62. PubMed ID: 9440723
[TBL] [Abstract][Full Text] [Related]
6. Phase I trial of continuous infusion 9-aminocamptothecin in patients with advanced solid tumors: 21-day infusion is an active well-tolerated regimen.
Sewak S; Sorich J; O'Leary J
Anticancer Drugs; 2006 Jun; 17(5):571-9. PubMed ID: 16702815
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of bryostatin 1 in the treatment of metastatic colorectal cancer.
Zonder JA; Shields AF; Zalupski M; Chaplen R; Heilbrun LK; Arlauskas P; Philip PA
Clin Cancer Res; 2001 Jan; 7(1):38-42. PubMed ID: 11205915
[TBL] [Abstract][Full Text] [Related]
8. A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study.
Weitman S; Langevin AM; Berkow RL; Thomas PJ; Hurwitz CA; Kraft AS; Dubowy RL; Smith DL; Bernstein M
Clin Cancer Res; 1999 Sep; 5(9):2344-8. PubMed ID: 10499603
[TBL] [Abstract][Full Text] [Related]
9. Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.
Ali S; Aranha O; Li Y; Pettit GR; Sarkar FH; Philip PA
Cancer Chemother Pharmacol; 2003 Sep; 52(3):235-46. PubMed ID: 12811511
[TBL] [Abstract][Full Text] [Related]
10. Analysis of long-term cognitive-enhancing effects of bryostatin-1 on the rabbit (Oryctolagus cuniculus) nictitating membrane response.
Wang D; Darwish DS; Schreurs BG; Alkon DL
Behav Pharmacol; 2008 May; 19(3):245-56. PubMed ID: 18469542
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of the combination of bryostatin-1 and cisplatin in advanced or recurrent carcinoma of the cervix: a New York Gynecologic Oncology Group study.
Nezhat F; Wadler S; Muggia F; Mandeli J; Goldberg G; Rahaman J; Runowicz C; Murgo AJ; Gardner GJ
Gynecol Oncol; 2004 Apr; 93(1):144-8. PubMed ID: 15047228
[TBL] [Abstract][Full Text] [Related]
13. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
14. Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
Lilenbaum RC; Miller AA; Batist G; Bernard S; Hollis DR; Rosner GL; Egorin MJ; Schilsky RL; Ratain MJ
J Clin Oncol; 1998 Oct; 16(10):3302-9. PubMed ID: 9779705
[TBL] [Abstract][Full Text] [Related]
15. The effect of bryostatin on protein kinase C-regulated functions in human T lymphocytes and epidermal keratinocytes.
Galron D; Tamir A; Gelkop S; Grossman N; Isakov N
Immunol Lett; 1993 Dec; 39(1):17-22. PubMed ID: 8144186
[TBL] [Abstract][Full Text] [Related]
16. Heterogenous effects of bryostatin on human myeloid leukemia clonogenicity: dose and time scheduling dependency.
van der Hem KG; Schuurhuis GJ; Dräger AM; Odding JH; Huijgens PC
Leuk Res; 1996 Sep; 20(9):743-50. PubMed ID: 8947584
[TBL] [Abstract][Full Text] [Related]
17. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of 3-week schedule of irinotecan combined with cisplatin in patients with advanced solid tumors.
de Jonge MJ; Sparreboom A; Planting AS; van der Burg ME; de Boer-Dennert MM; ter Steeg J; Jacques C; Verweij J
J Clin Oncol; 2000 Jan; 18(1):187-94. PubMed ID: 10623709
[TBL] [Abstract][Full Text] [Related]
19. A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors.
Otterson GA; Lavelle J; Villalona-Calero MA; Shah M; Wei X; Chan KK; Fischer B; Grever M
Invest New Drugs; 2005 Dec; 23(6):555-62. PubMed ID: 16034523
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia.
Cragg LH; Andreeff M; Feldman E; Roberts J; Murgo A; Winning M; Tombes MB; Roboz G; Kramer L; Grant S
Clin Cancer Res; 2002 Jul; 8(7):2123-33. PubMed ID: 12114412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
